tradingkey.logo

Sol Gel Technologies Ltd

SLGL
33.500USD
-2.000-5.63%
Fechamento 11/04, 16:00ETCotações atrasadas em 15 min
93.32MValor de mercado
PerdaP/L TTM

Sol Gel Technologies Ltd

33.500
-2.000-5.63%

Mais detalhes de Sol Gel Technologies Ltd Empresa

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Informações de Sol Gel Technologies Ltd

Código da empresaSLGL
Nome da EmpresaSol Gel Technologies Ltd
Data de listagemFeb 01, 2018
CEO- -
Número de funcionários34
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 01
EndereçoGolda Meir 7
CidadeNESS-ZIONA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal- -
Telefone97289313433
Sitehttp://www.sol-gel.com
Código da empresaSLGL
Data de listagemFeb 01, 2018
CEO- -

Executivos da empresa Sol Gel Technologies Ltd

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Nissim Bilman
Mr. Nissim Bilman
Vice President - Quality
Vice President - Quality
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+275.67%
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Ms. Yaffa Krindel
Ms. Yaffa Krindel
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
Mr. Eyal Ben-Or
Mr. Eyal Ben-Or
Chief Financial Officer
Chief Financial Officer
--
--

Detalhamento da receita

Sem dados
Sem dados
Por Empresa
Por Região
Sem dados

Distribuição de ações

Atualizado em: ter, 4 de nov
Atualizado em: ter, 4 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
M.Arkin Dermatology, Ltd.
64.86%
Arkin (Moshe)
5.14%
Opaleye Management Inc.
5.00%
Migdal Insurance and Financial Holdings Ltd
4.41%
Raymond James Financial Services Advisors, Inc.
0.28%
Outro
20.31%
Investidores
Investidores
Proporção
M.Arkin Dermatology, Ltd.
64.86%
Arkin (Moshe)
5.14%
Opaleye Management Inc.
5.00%
Migdal Insurance and Financial Holdings Ltd
4.41%
Raymond James Financial Services Advisors, Inc.
0.28%
Outro
20.31%
Tipos de investidores
Investidores
Proporção
Corporation
64.86%
Investment Advisor
9.43%
Individual Investor
5.14%
Hedge Fund
5.00%
Insurance Company
4.41%
Research Firm
0.29%
Outro
10.86%

Participação acionária institucional

Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
35
533.06K
19.14%
-233.10K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
2023Q2
29
22.04M
83.43%
-335.52K
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Opaleye Management Inc.
139.39K
5%
+139.39K
--
Aug 22, 2025
Migdal Insurance and Financial Holdings Ltd
122.75K
4.41%
--
--
Jun 30, 2025
Raymond James Financial Services Advisors, Inc.
7.81K
0.28%
-871.00
-10.03%
Jun 30, 2025
UBS Financial Services, Inc.
7.34K
0.26%
+3.53K
+92.62%
Jun 30, 2025
Morgan Stanley & Co. LLC
5.33K
0.19%
-3.90K
-42.24%
Jun 30, 2025
Raymond James & Associates, Inc.
2.68K
0.1%
+162.00
+6.44%
Jun 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
-200.00
-38.76%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
308.00
0.01%
-1.00
-0.32%
Jun 30, 2025
Ver Mais

ETFs Relacionados

Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proporção0%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI